Brandywine Oak Private Wealth LLC Buys 946 Shares of AstraZeneca PLC $AZN

Brandywine Oak Private Wealth LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 1.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,470 shares of the company’s stock after purchasing an additional 946 shares during the period. Brandywine Oak Private Wealth LLC’s holdings in AstraZeneca were worth $4,645,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AZN. Lindbrook Capital LLC lifted its holdings in AstraZeneca by 1.9% in the first quarter. Lindbrook Capital LLC now owns 7,574 shares of the company’s stock valued at $557,000 after buying an additional 141 shares during the period. Principal Securities Inc. lifted its holdings in AstraZeneca by 0.5% in the first quarter. Principal Securities Inc. now owns 28,053 shares of the company’s stock valued at $2,062,000 after buying an additional 142 shares during the period. Sage Mountain Advisors LLC lifted its holdings in AstraZeneca by 3.4% in the first quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company’s stock valued at $329,000 after buying an additional 147 shares during the period. Evergreen Capital Management LLC lifted its holdings in AstraZeneca by 0.7% in the first quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock valued at $1,743,000 after buying an additional 155 shares during the period. Finally, Grimes & Company Inc. lifted its holdings in AstraZeneca by 3.0% in the second quarter. Grimes & Company Inc. now owns 5,290 shares of the company’s stock valued at $370,000 after buying an additional 155 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AZN. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a report on Wednesday, July 9th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Trading Down 0.4%

NASDAQ:AZN opened at $85.04 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a 50-day moving average of $78.97 and a 200-day moving average of $73.37. The company has a market cap of $263.74 billion, a PE ratio of 31.97, a PEG ratio of 1.57 and a beta of 0.36. AstraZeneca PLC has a one year low of $61.24 and a one year high of $86.57.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same period in the previous year, the firm posted $1.24 earnings per share. The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. As a group, equities research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were issued a dividend of $0.505 per share. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s payout ratio is 37.97%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.